Hims Testosterone Support review: is it worth it?

What is Hims Testosterone Support and how does it work?

Hims (Hims & Hers Health) is a publicly traded direct-to-consumer telehealth company that connects patients with licensed clinicians and ships prescription and over-the-counter products to the door. Its "Testosterone Support" offering is a hormone-health *program*, not a single shelf product. The core of that program is enclomiphene citrate, marketed by Hims under names like Testosterone Rx and Testosterone Rx+.

This is an important distinction that many "best testosterone booster" roundups blur: most products in that category are herbal supplements (ashwagandha, fenugreek, zinc, tongkat ali). Hims Testosterone Support is fundamentally different. Its active ingredient is a selective estrogen receptor modulator (SERM) — a real pharmaceutical that works on the brain's hormonal control system. The supporting nutrients (zinc, B6, B12, L-arginine) that Hims may add to its blend are secondary; they are not what makes the product work.

Mechanistically, testosterone production is governed by the hypothalamic–pituitary–gonadal (HPG) axis. The brain releases gonadotropin-releasing hormone, which tells the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn tell the testes to produce testosterone and sperm. Estrogen normally provides negative feedback that throttles this loop. Enclomiphene is the *trans*-isomer of clomiphene; it blocks estrogen receptors in the hypothalamus and pituitary, removing that brake. The pituitary then secretes more LH and FSH, and the testes ramp up endogenous testosterone (NIH/NCBI; Wiehle et al., BJU International 2013).

This is the key conceptual advantage Hims promotes, and it is real: because enclomiphene raises your *own* LH and FSH rather than supplying testosterone from outside, it tends to preserve fertility and testicular function — whereas conventional testosterone replacement therapy (TRT) suppresses the HPG axis and can shrink the testes and reduce sperm counts (AUA Guideline on Evaluation and Management of Testosterone Deficiency).

What does the program actually include?

The service is a structured telehealth flow rather than a product you simply add to a cart:

• Online intake. You complete a medical questionnaire covering symptoms (low libido, fatigue, low mood, poor recovery), history, and goals.
• Lab testing. Legitimate hormone treatment requires bloodwork. Hims directs patients to lab testing (typically total testosterone, and often LH, FSH, estradiol, and related markers) before a prescription is issued.
• Clinician review. A licensed provider reviews your labs and history asynchronously and decides whether treatment is appropriate.
• The medication. If approved, you receive a daily oral product. Depending on the plan and clinician judgment, this can be enclomiphene alone, or a combination capsule adding tadalafil (the generic of Cialis, for erectile function) and supportive nutrients.
• Ongoing membership. Hims operates on a subscription model with periodic check-ins and refills.

How well does enclomiphene actually work?

The evidence base for enclomiphene is genuine but modest in scale, drawn mostly from small-to-medium phase II trials and recent meta-analyses rather than large, long-term outcome studies.

The most-cited pivotal work is Wiehle et al. (BJU International 2013; PMID 23875626), a randomized phase II study comparing three doses of enclomiphene (6.25, 12.5, and 25 mg) against transdermal testosterone gel in men with secondary hypogonadism. Enclomiphene significantly raised both total testosterone and LH, restoring testosterone into the normal range while — critically — *increasing* LH and FSH, the opposite of what topical testosterone did. Follow-up phase II work published in *Fertility and Sterility* (2014) reinforced that enclomiphene raised testosterone while preserving sperm output, where exogenous testosterone gel suppressed it.

More recently, a 2025 systematic review and meta-analysis of randomized controlled trials (Archives of Endocrinology and Metabolism 2025; PMC12510335; PMID 41066380) pooled 10 trials and 819 patients and found that SERM therapy (clomiphene/enclomiphene) produced a clinically meaningful rise in total testosterone — a mean difference of roughly +274 ng/dL versus placebo (95% CI ~192–356) — alongside increases in LH and FSH and preserved spermatogenesis. Notably, that same analysis found no statistically significant difference in total testosterone between SERMs and testosterone gel, supporting the view that enclomiphene can achieve testosterone levels broadly *comparable* to transdermal TRT.

A balanced reading: enclomiphene reliably *raises the number* (serum testosterone) and protects fertility. What is far less established is whether it consistently delivers the *symptom* outcomes men actually want — durable improvements in energy, libido, mood, body composition — in large populations over the long term. This gap is not academic. It is closely tied to why enclomiphene was never approved as a finished drug (see below): regulators wanted trials designed to prove clinical benefit, not just a higher number. Most patient-facing timelines, including the "feel better in 4–6 weeks" framing, are reasonable expectations but are not guarantees backed by large outcome trials.

Is it FDA-approved? (The single most important fact)

No. Enclomiphene is not FDA-approved. This is the most consequential thing to understand before starting, and it is frequently glossed over.

Enclomiphene was developed as a branded drug called Androxal (by Repros Therapeutics). It completed phase II and phase III trials, but in December 2015 the FDA issued a Complete Response Letter declining approval — the agency concluded that, in light of evolving science, the Phase 3 study design was no longer adequate to demonstrate clinical benefit and asked the sponsor to run additional Phase 3 studies. The European Medicines Agency's CHMP likewise refused marketing authorization (2018). Development of enclomiphene as a standalone approved drug was ultimately discontinued in 2021 (Repros Therapeutics regulatory filings; Drugs.com history; Wikipedia: Enclomifene, citing regulatory record).

Because there is no FDA-approved enclomiphene product, Hims dispenses it as a compounded medication made by compounding pharmacies. Compounded drugs are legal and can be prescribed off-label by licensed clinicians, but as the FDA itself states, the FDA does not verify the safety, effectiveness, or quality of compounded drugs before they reach patients. The Department of Defense's Operation Supplement Safety (OPSS) also flags that clomiphene and enclomiphene are *drugs, not dietary supplements*, and should never be treated as benign "boosters."

The tadalafil component, by contrast, is FDA-approved (for erectile dysfunction and BPH). But the *combination* capsule — enclomiphene plus tadalafil plus nutrients — is a compounded formulation that has never been approved or studied as a finished product.

Who is it best for, and who should skip it?

Best for:

• Men with lab-confirmed secondary hypogonadism (low testosterone driven by inadequate LH/FSH signaling, not testicular failure).
• Men who want to preserve fertility or testicular size and therefore should avoid conventional testosterone monotherapy. The AUA guideline explicitly recommends *against* prescribing testosterone to men who desire current or future fertility — making a SERM a rational, fertility-sparing alternative for the right patient.
• Men who prefer a daily oral pill over injections, gels, or pellets and value telehealth convenience.

Who should skip it or proceed only with specialist care:

• Men with normal testosterone chasing a performance edge. There is no evidence enclomiphene helps men with already-normal levels, and you would be taking an unapproved drug for no demonstrated benefit.
• Men with primary hypogonadism (testicular failure). If the testes themselves cannot respond, raising LH/FSH accomplishes little.
• Men who want a non-prescription herbal supplement — this is not that.
• Anyone uncomfortable taking a compounded, non-FDA-approved medication, or who has a history of thromboembolic disease, certain eye/vision disorders, liver disease, or hormone-sensitive conditions. These warrant in-person evaluation, ideally with a urologist or endocrinologist.

Side effects, safety, and interactions

Enclomiphene's reported side effects, drawn from its SERM class and trial data, include headache, hot flashes, nausea, mood changes, and breast tenderness/discomfort (gynecomastia signals). As an estrogen-receptor modulator, the SERM class carries theoretical concerns around vision changes and venous thromboembolism (blood clots) — the labeled risks for clomiphene — though these are uncommon at the doses used. Because enclomiphene raises estradiol as well as testosterone in some men, estradiol monitoring matters.

If your prescription includes tadalafil, layer on its known effects: headache, flushing, indigestion, nasal congestion, back pain, and dizziness. Tadalafil has a hard contraindication with nitrates (used for chest pain) and interacts with alpha-blockers and certain blood-pressure medications — combinations that can cause dangerous drops in blood pressure (FDA tadalafil label).

The overarching safety caveat returns to the compounding issue: with an unapproved compounded drug, dose accuracy and product quality are not independently verified, and long-term safety data in this specific use are limited. Treatment should always include baseline and follow-up bloodwork and clinician oversight — not a fire-and-forget subscription.

How to take it

Hims dispenses enclomiphene-based products as a once-daily oral capsule, designed to fold any tadalafil and nutrient components into a single pill for adherence. Studied enclomiphene doses cluster around 12.5–25 mg daily, with clinicians titrating based on follow-up labs. Improvements in testosterone are biochemically measurable within roughly two weeks, but men typically describe symptom changes over 4–8 weeks, with fuller effects taking a few months. Periodic retesting (testosterone, estradiol, and a hematocrit/CBC to watch for blood thickening) is the responsible standard.

Cost and value

Reported pricing varies by plan and what's bundled. At launch, Hims advertised its enclomiphene plans priced by prepaid commitment: roughly $199/month on a 3-month plan, $139/month on a 5-month plan, and $99/month on a 10-month plan — so the lowest monthly figure requires the longest upfront commitment. Prices and bundles can change, and lab fees or the consultation may be additional depending on the plan.

On value, the honest assessment is mixed. The monthly cost is reasonable relative to in-person hormone clinics, and the all-in-one daily pill is convenient. But you are paying a recurring subscription for a compounded, non-FDA-approved drug, often with a multi-month upfront commitment that limits flexibility if it doesn't work for you. Third-party reviews repeatedly note that the Hims brand premium exceeds the intrinsic cost of the ingredients. The math only favors Hims if you genuinely need a fertility-sparing oral therapy and value the streamlined telehealth experience.

How does it compare to the alternatives?

• Conventional TRT (testosterone gels, injections, pellets, and oral testosterone): FDA-approved, decades of data, and the standard for symptomatic, lab-confirmed low testosterone. Downsides: it suppresses the HPG axis, impairs fertility, and can shrink the testes. Hims itself also offers conventional testosterone options (including branded oral testosterone) where clinically indicated, and other telehealth TRT services compete in this space. Enclomiphene's whole pitch is being the fertility-preserving alternative to this.
• Clomiphene (Clomid): The older, cheaper, FDA-approved (for female infertility) drug prescribed off-label to men. Enclomiphene is its purified *trans*-isomer, marketed as having a cleaner side-effect profile, but the comparative clinical advantage over plain clomiphene is not firmly established by large trials, and clomiphene is far less expensive.
• Other telehealth hormone programs (e.g., Hone, Maximus, dedicated men's clinics): Compete on price, in-depth monitoring, and protocol breadth. Some emphasize more rigorous lab panels and physician contact.
• OTC "testosterone boosters": Ashwagandha, fenugreek, zinc, tongkat ali. These are supplements with modest, inconsistent evidence and no prescription required — a different category entirely. They will not meaningfully treat clinical hypogonadism.

The bottom line

Hims Testosterone Support is a legitimate, clinician-gated telehealth pathway to enclomiphene, a real drug with a sound mechanism and genuine — if modestly sized — evidence that it raises testosterone while preserving fertility. For the specific patient it suits best — a man with lab-confirmed secondary hypogonadism who wants to keep his fertility and prefers a daily pill — it is a reasonable, convenient option, and the fertility-sparing logic is supported by the AUA guideline's caution against testosterone monotherapy in men who want children.

But two facts must anchor any decision. First, enclomiphene is not FDA-approved and is dispensed as a compounded medication whose quality and safety the FDA does not vet — the agency declined approval, faulting the trial design for not adequately demonstrating clinical benefit beyond the rise in testosterone. Second, this is a prescription drug, not a supplement, requiring real lab work and ongoing monitoring; it is not for men with normal levels seeking a boost. Treat it as a medical decision, insist on bloodwork before and during treatment, and ideally loop in a urologist or endocrinologist rather than relying on a subscription alone. Used that way, by the right person, it can be a sensible tool. Used casually, it is an unapproved drug taken without the oversight it demands.